Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01835483 · ClinicalTrials.gov registry record
Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 867
- Enrollment target
NCT01835483: Completed study, sponsored by Sequenom.
NCT01835483 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 867 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01835483 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 867 participants
- Enrollment target
Study Summary
To establish the overall agreement of the MassPLEX Factor II and Factor V Leiden Genotyping Test with bi-directional DNA sequencing for Factor II and Factor V Leiden.
Primary Outcome
Overall percent agreement of the FII/FVL Test results to the bi-directional DNA sequencing results.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 867 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-07 |
What the finished NCT01835483 record still lists
NCT01835483 is an observational study that tracks outcomes without assigning an intervention. The registered 867 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01835483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01835483 about?
NCT01835483 is a clinical study titled "Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test". To establish the overall agreement of the MassPLEX Factor II and Factor V Leiden Genotyping Test with bi-directional DNA sequencing for Factor II and Factor V Leiden.
What is the current status of trial NCT01835483?
This trial is currently completed. The enrollment target is 867 participants. The study started on 2013-05. Estimated completion is 2013-07.
Who is sponsoring clinical trial NCT01835483?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT05369052 · 865 participants · Phase 3
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia